Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension

Vascular Pharmacology

Volumn 46, Issue 2, 2007, Pages 144-151

  Elmarakby, Ahmed A ^a   Williams, Jan M ^a   Imig, John D ^a   Pollock, Jennifer S ^a   Pollock, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

8 isoprostane; Angiotensin converting enzyme inhibitors; Arterial pressure; Oxidative stress; Rats; Superoxide

Indexed keywords

8 ISOPROSTANE; ANGIOTENSIN II; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; KININ; SUPEROXIDE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FATTY ACID BLOOD LEVEL; HYPERTENSION; INFUSION; KIDNEY CORTEX; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; BRADYKININ; CHRONIC DISEASE; CYCLIC N-OXIDES; DINOPROST; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENALAPRIL; HYDROGEN PEROXIDE; HYPERTENSION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, BRADYKININ; SPIN LABELS; SUPEROXIDES; TIME FACTORS;

EID: 33845561904     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.09.004     Document Type: Article

References (39)

1. Alexander B.T., Cockrell K.L., Rinewalt A.N., Herrington J.N., and Granger J.P. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am. J. Physiol., Regul. Integr. Comp. Physiol. 280 (2001) R1388-R1392
2. Bayorh M.A., Mann G., Walton M., and Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats. Clin. Exp. Hypertens. 28 (2006) 121-132
3. Bell J.P., Mosfer S.I., Lang D., Donaldson F., and Lewis M.J. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1704-H1710
4. Beswick R.A., Zhang H., Marable D., Catravas J.D., Hill W.D., and Webb R.C. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37 (2001) 781-786
5. 1 bradykinin receptor in normotension and hypertension. Circ. Res. 88 (2001) 275-281
6. Elmarakby A.A., Morsing P., and Pollock D.M. Regulation of cardiovascular signaling by kinins and products of similar converting-enzyme systems: enalapril attenuates endothelin-1-induced hypertension via increased kinin survival. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1899-H1903
7. Elmarakby A.A., Loomis E.D., Pollock J.S., and Pollock D.M. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 45 (2005) 283-287
8. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 (1994) 1141-1148
9. Hoagland K.M., Maier K.G., and Roman R.J. Contributions of 20-HETE to the antihypertensive effects of tempol in Dahl salt-sensitive rats. Hypertension 41 (2003) 697-702
10. 1 receptor. J. Biol. Chem. 277 (2002) 16847-16852
11. Kawada N., Imai E., Karber A., Welch W.J., and Wilcox C.S. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J. Am. Soc. Nephrol. 13 (2002) 2860-2868
12. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., and Harrison D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95 (1997) 588-593
13. Linz W., Wiemer G., Gohlke P., Unger T., and Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47 (1995) 25-49
14. Loomis E.D., Sullivan J.C., Osmond D.A., Pollock D.M., and Pollock J.S. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled NOS in the rat aorta. J. Pharmacol. Exp. Ther. 315 (2005) 1058-1064
15. Lopez B., Salom M.G., Arregui B., Valero F., and Fenoy F.J. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 42 (2003) 1150-1156
16. 2 leads to hypertension. Hypertension 42 (2003) 25-30
17. 1 receptors for kinins. Pharmacol. Rev. 50 (1998) 357-386
18. 1 receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105 (2002) 627-632
19. 1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc. Res. 48 (2000) 194-210
20. 1 receptor regulation. Circulation 105 (2002) 530-536
21. Nishiyama A., Fukui T., Fujisawa Y., Rahman M., Tian R.X., Kimura S., and Abe Y. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37 (2001) 77-83
22. Ortiz M.C., Manriquez M.C., Romero J.C., and Juncos L.A. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 38 (2001) 655-659
23. Pasquie J.L., Herizi A., Jover B., and Mimran A. Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Hypertension 33 (1999) 830-834
24. Pollock D.M., and Pollock J.S. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol., Renal Fluid Electrolyte Physiol. 281 (2001) F144-F150
25. Pollock D.M., and Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am. J. Physiol., Regul. Integr. Comp. Physiol. 275 (1998) R1719-R1723
26. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
27. Reckelhoff J.F., and Romero J.C. Role of oxidative stress in angiotensin-induced hypertension. Am. J. Physiol., Regul. Integr. Comp. Physiol. 284 (2003) R893-R912
28. Rossi G.P., Cavallin M., Rizzoni D., Bova S., Mazzocchi G., Agabiti-Rosei E., Nussdorfer G.G., and Pessina A.C. Dual ACE and NEP inhibitor MDL-100, 240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor. J. Hypertens. 20 7 (2002) 1451-1459
29. Sasser J.M., Pollock J.S., and Pollock D.M. Renal endothelin in chronic angiotensin II hypertension. Am. J. Physiol., Regul. Integr. Comp. Physiol. 283 (2002) R243-R248
30. Schnackenberg C.G., and Wilcox C.S. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 33 (1999) 424-428
31. 2 receptor activation in angiotensin II-dependent hypertension. J. Hypertens. 24 7 (2006) 1419-14127
32. Somers M.J., Mavromatis K., Galis Z.S., and Harrison D.G. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101 (2000) 1722-1728
33. Sullivan J.C., Pollock D.M., and Pollock J.S. Altered nitric oxide synthase 3 distribution in mesenteric arteries of hypertensive rats. Hypertension 39 (2002) 597-602
34. Tom B., Dendorfer A., and Jan Danser A.H. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?. Int. J. Biochem. Cell Biol. 35 (2003) 792-801
35. B receptor blockade in rats on a high-salt diet. Hypertension 44 (2004) 770-775
36. Xu H., Fink G.D., and Galligan J.J. Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2- in DOCA-salt rats. Hypertension 43 (2004) 329-334
37. 1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45 (2005) 747-753
38. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 (2000) 145-153
39. Zhang G.X., Kimura S., Nishiyama A., Shokoji T., Rahman M., and Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 43 (2004) 117-124